| 1 |
35169023 | Effect of CYB2B6 (c.516G>T), CYP2C9 (c.1075A>C) and UGT1A9 (c.98T>C) polymorphisms on propofol pharmacokinetics in patients submitted to colonoscopy: a cohort study. | 2022 Feb 15 |
1 |
| 2 |
32021384 | The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children. | 2020 |
3 |
| 3 |
27826892 | The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia. | 2017 May |
2 |
| 4 |
25832633 | Impact of CYP2C9 polymorphism found in the Chinese population on the metabolism of propofol in vitro. | 2015 |
5 |
| 5 |
24891132 | Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment. | 2014 Dec |
1 |
| 6 |
23640947 | The impact of genetic factors on response to anaesthetics. | 2013 |
1 |
| 7 |
19442086 | Polymorphic drug metabolism in anaesthesia. | 2009 Mar |
1 |
| 8 |
11753007 | Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. | 2002 Jan |
1 |
| 9 |
11135730 | Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. | 2001 Jan |
2 |
| 10 |
9764927 | Effects of propofol on human hepatic microsomal cytochrome P450 activities. | 1998 Sep |
1 |